Determination of TB treatment outcomes
TB
ADVERSE EVENTS
At the end of therapy treatment (9 months for participants that qualify for shorter MDR-TB/RR-TB treatment regimen and 18 months for those selected for the longer MDR-TB/RR-TB treatment regimen), clinical and laboratory information is routinely compiled by each MDR-TB centre and forwarded to the National TB Program (NTP) review committee for discussion on consensus on treatment outcome based on a specified criterion (Table Description of MDR-TB treatment outcomes1. A patient who has culture converted and2. Received treatment for a total duration of 9–11 months and3. Has at least 3 consecutive negative TB cultures atleast 30 days apart and4. No evidence of clinical deterioration1. A patient who has culture converted and2. Received treatment for a total duration of 9–11 months and3. Has less than 3 consecutive negative TB cultures at least 30 days apart and4. No evidence of clinical deterioration1. A patient who failed to culture convert by month 5 (shorter regimen) or month 6 (longer regimen) or2. In the initial 6 months of treatment more than 2 of 5 cultures are positive or3. Treatment stopped due to adverse events4. Permanent discontinuation of two Group A drugs (BDQ, LZD, or LFX) in the first 6 months of the modified shorter regimen or5. More than 2 new drugs added because of poor clinical response or6. Panel decision to terminate any further DR-TB treatment